Mirko L. Farina

Universitetskaya St, 1, 420500
Innopolis, TA, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 112 publications

Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy.

Mitigating HLA Disparity in AML Transplantation: Comparable Outcomes After Haploidentical and 9/10 Mismatched Unrelated Donor Transplantation With Treosulfan and PTCy.

Journal: American journal of hematology

Published: May 27, 2026

PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.

PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.

Journal: European journal of nuclear medicine and molecular imaging

Published: May 15, 2026

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. Cancers 2025, 17, 3278.

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. Cancers 2025, 17, 3278.

Journal: Cancers

Published: May 08, 2026

Cytokine Release Syndrome after Haploidentical Transplantation is Associated with Improved Survival Without Increasing Transplant-Related Mortality.

Cytokine Release Syndrome after Haploidentical Transplantation is Associated with Improved Survival Without Increasing Transplant-Related Mortality.

Journal: Mediterranean journal of hematology and infectious diseases

Published: May 07, 2026

Fluoroquinolone-Free Prophylaxis and Impact on Bacterial Infections, Resistance, and Survival in Allo-HSCT: 5-Year Follow-up of the BATMO Protocol (Best Anti-microbical Therapy Trapianto di Midollo Osseo).

Fluoroquinolone-Free Prophylaxis and Impact on Bacterial Infections, Resistance, and Survival in Allo-HSCT: 5-Year Follow-up of the BATMO Protocol (Best Anti-microbical Therapy Trapianto di Midollo Osseo).

Journal: Open forum infectious diseases

Published: April 09, 2026

Calcineurin inhibitor-induced pain syndrome: an uncommon side effect of immunosuppressive therapy after allogeneic hematopoietic stem cell transplant. a case report and review of the literature.

Calcineurin inhibitor-induced pain syndrome: an uncommon side effect of immunosuppressive therapy after allogeneic hematopoietic stem cell transplant. a case report and review of the literature.

Journal: Annals of hematology

Published: February 06, 2026

Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study.

Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study.

Journal: HemaSphere

Published: February 05, 2026

Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study.

Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 22, 2026

A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.

A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remission.

Journal: Bone marrow transplantation

Published: January 21, 2026

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Journal: Cancer

Published: December 16, 2025

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.

Journal: The Lancet. Haematology

Published: December 16, 2025

NGS-Driven Digital PCR for Personalized and Accurate Measurable Residual Disease Assessment in Acute Myeloid Leukemia.

NGS-Driven Digital PCR for Personalized and Accurate Measurable Residual Disease Assessment in Acute Myeloid Leukemia.

Journal: American journal of hematology

Published: November 30, 2025

Showing 1-12 of 112

Last Updated: 09/26/2026